U.S. markets close in 5 hours 33 minutes
  • S&P 500

    3,832.69
    +1.30 (+0.03%)
     
  • Dow 30

    30,989.17
    +21.35 (+0.07%)
     
  • Nasdaq

    11,319.61
    -2.62 (-0.02%)
     
  • Russell 2000

    1,733.27
    -8.06 (-0.46%)
     
  • Crude Oil

    96.48
    -3.02 (-3.04%)
     
  • Gold

    1,750.80
    -13.10 (-0.74%)
     
  • Silver

    19.08
    -0.04 (-0.19%)
     
  • EUR/USD

    1.0177
    -0.0093 (-0.91%)
     
  • 10-Yr Bond

    2.8350
    +0.0260 (+0.93%)
     
  • GBP/USD

    1.1902
    -0.0050 (-0.42%)
     
  • USD/JPY

    135.7240
    -0.1180 (-0.09%)
     
  • BTC-USD

    20,137.81
    +676.07 (+3.47%)
     
  • CMC Crypto 200

    436.07
    +0.55 (+0.13%)
     
  • FTSE 100

    7,137.74
    +112.27 (+1.60%)
     
  • Nikkei 225

    26,107.65
    -315.82 (-1.20%)
     

Moderna (MRNA) Gains But Lags Market: What You Should Know

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Moderna (MRNA) closed the most recent trading day at $129.99, moving +1.53% from the previous trading session. This move lagged the S&P 500's daily gain of 2.45%. Elsewhere, the Dow gained 2.15%, while the tech-heavy Nasdaq added 0.18%.

Prior to today's trading, shares of the biotechnology company had lost 6.97% over the past month. This has was narrower than the Medical sector's loss of 7.42% and lagged the S&P 500's loss of 5.71% in that time.

Wall Street will be looking for positivity from Moderna as it approaches its next earnings report date. The company is expected to report EPS of $4.73, down 26.78% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $4.08 billion, down 6.23% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of $27.27 per share and revenue of $22.39 billion, which would represent changes of -3.61% and +21.21%, respectively, from the prior year.

Investors might also notice recent changes to analyst estimates for Moderna. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.23% higher within the past month. Moderna currently has a Zacks Rank of #3 (Hold).

Looking at its valuation, Moderna is holding a Forward P/E ratio of 4.69. Its industry sports an average Forward P/E of 20.02, so we one might conclude that Moderna is trading at a discount comparatively.

We can also see that MRNA currently has a PEG ratio of 0.72. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.08 based on yesterday's closing prices.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 105, putting it in the top 42% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
To read this article on Zacks.com click here.